在复发性/耐药性AML中使用Venetoclax加上cytarabine和azacitidine:一项开放式,单臂,第二阶段研究
Liangshun You1, Yi Liu2, Wenyuan Mai2
1Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, Zhejiang, People's Republic of China; Zhejiang Provincial Clinical Research Center for Hematologic Diseases, Hangzhou 310003, Zhejiang, People's Republic of China; Zhejiang Province Key Laboratory of Hematology Oncology Diagnosis and Treatment, Hangzhou 310003, Zhejiang, People's Republic of China.
European journal of cancer (Oxford, England : 1990)
|March 12, 2024
概括
结合Venetoclax,Cytarabine和Azacitidine的VAA疗法在复发性/耐药性急性髓性白血病方面显示出显著的前景. 这种治疗在R/RAML患者中实现了高缓解率和可管理的安全概况.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 复发性/耐药性急性髓性白血病 (R/RAML) 是一个重大的临床挑战,结果不佳.
- 基于Venetoclax (VEN) 的疗法已成为R/R AML的有希望的治疗策略.
研究的目的:
- 评估VAA治疗方案 (Venetoclax,Cytarabine,Azacitidine) 在R/RAML患者的疗效和安全性.
- 将复合完全缓解率 (CRc) 作为主要终点进行评估.
主要方法:
- 一项涉及30名R/RAML患者的第二阶段研究.
- 使用了Venetoclax (VEN) 的逐步加大剂量策略.
- 组合治疗包括VEN的Cytarabine和Azacitidine.
主要成果:
- 综合完全缓解率 (CRc) 为63.3% (19/30),其中36.7%达到完全反应 (CR) 和26.7%的CR不完全恢复血清 (CRi).
- 可测量的残留疾病在达到CRc.的73.7%的患者中无法检测到.
- 平均整体存活期未达到,反应的平均持续时间为18.3个月.
结论:
- VAA疗法在R/RAML患者中表现出显著的疗效.
- 治疗方案与可管理的安全性相关,常见的不良事件包括中性质减退和贫血.
- VAA疗法代表了R/RAML的可行和有效的治疗选择.
关键词:
亚扎提丁氨酸是一种阿扎提丁氨酸.赛塔拉宾可以作为一种药物.复发性和耐火性AML的复发和耐火性AML的复发和耐火性AML的复发.威尼托克拉克斯 (Venetoclax) 是一个属于威尼托克拉克斯的地区.更多相关视频
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
相关概念视频
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...